101. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary.
A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995
Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001; 38: 2101-2113.
102. Reithmann C, Reber D, Kozlik-Feldmann R, et al. A postreceptor defect of adenylyl cyclase in severely failing myocardium from children with
congenital heart disease. Eur J Pharmacol 1997; 330: 79-86.
103. Läer S, Mir TS, Behn F, et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic
parameters. Am Heart J 2002; 143: 916-922.
104. Ohuchi H, Takasugi H, Ohashi H, et al. Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activities
in patients with congenital heart disease. Circulation 2003; 108: 2368-2676.
105. Rosenthal D, Chrisant MR, Edens E, et al. International Society for Heart and Lung Transplantation: Practice guidelines for management of heart
failure in children. J Heart Lung Transplant 2004; 12: 1313-1333.
106. Felker GM, O’Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 2001; 142: 393-401.
107. Lowes BD, Simon MA, Tsvetkova TO, et al. Inotropes in the beta-blocker era. Clin Cardiol 2000; 23: III11-6.
108. Silka M, Szmuszkovicz J. Arrhythmias and sudden cardiac death in pediatric heart failure. In: Shaddy R., Wernovsky G., ed. Pediatric Heart
Failure, Boca Raton, FL: Taylor & Francis 2005: 433-479.
109. Wagoner L.E., Starling RC, O’Connor CM. Cardiac function and heart failure. J Am Coll Cardiol 2006; 47: D18-D22.
110. Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006; 296: 1867-1876.
111. Azevedo VM, Santos MA, Albanesi Filho FM, et al. Outcome factors of idiopathic dilated cardiomyopathy in children: A long-term follow-up review.
Cardiol Young 2007; 17: 175-184.
112. Asanoi H, Kameyama T, Ishizaka S, et al. Energetically optimal left ventricular pressure for the failing human heart. Circulation 1996; 93: 67-73.
113. Kantor PF, Mertens LL. Clinical practice. Heart failure in children. Part I: clinical evaluation, diagnostic testing, and initial medical management.
Eur J Pediatr 2010; 169: 269-279.
114. Kantor PF, Mertens LL. Clinical practice. Heart failure in children. Part II: current maintenance therapy and new therapeutic approaches. Eur
J Pediatr 2010; 169: 403-410.
115. Osadchii OE. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. Cardiovasc Drugs Ther 2007;
21: 171-194.
116. Yan C, Miller CL, Abe J. Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res 2007; 100: 489-501.
117. Movsesian M, Stehlik J, Vandeput F, et al. Phosphodiesterase inhibition in heart failure. Heart Fail Rev 2009; 14: 255-263.
118. 梶本克也，指田由紀子，笠貫 宏．急性心不全に強心剤を使うべき．呼と循 2004; 52: 897-902.
119. Brixius K, Hoyer HK, Schwinger RHG. Ca2+-Sensitisers -A promising option to treat heart failure? Cardiovas Drug Therap 2005; 19: 423-428.
120. De Luca L, Colucci WS, Nieminen MS, et al. Evidencebased use of levosimendan in different clinical settings. Euro Heart J 2006; 27: 1908-1920.
121. Packer M. The Randomized multicenter Evaluation of Intravenous levosimendan Efficacy-2 (REVIVE-2) trial. Latebreaking Clinical Trials. American
Heart Association, Annual Scientific Session, Dallas, TX, 13-16 November 2005.
122. Mebazaa A. The SURVival of Patients with Acute Heart Failure in Need of IntraVEnous Inotropic Support (SURVIVE) trial. Late-breaking Clinical
Trials. American Heart Association, Annual Scientific Session. Dallas, TX, 13-16 November 2005.
123. 2009 Focused Updat: ACCF/AHAs Guidelines for the diagnosis and management of heart failure in adults. Circulation 2009; 119: 1977-2016.
124. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008; 29: 2388-2442.
125. Amsallem E, Kasparian C, Haddour G, et al. Phosphodiesterase III inhibitors for heart failure (Review). The Cochrane Library 2009, Issue 1.
CD002230.
126. Guideline Summary NGC-5205 Cincinnati Children’s Hospital Medical Center. Evidence-based care guideline for inotropic support with
phosphodiesterase inhibitors after repair of tetralogy of Fallot. Cincinnati (OH): Cincinnati Children’s Hospital Medical Center; 2006 Mar.
127. Guideline Summary NGC-5211 Cincinnati Children’s Hospital Medical Center. Evidence-based care guideline for inotropic support with
phosphodiesterase inhibitors after arterial switch operation. Cincinnati (OH): Cincinnati Children’s Hospital Medical Center; 2006 Aug
128. 循環器病の診断と治療に関するガイドライン. 急性心不全治療ガイドライン（2006年改訂版）. http://www.j-circ. or.jp/guideline/pdf/JCS2006_maruyama_h.pdf
129. Parissis JT, Farmakis D, Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev 2007; 12: 149-156.
130. Duggal B, Pratap U, Slavik Z, et al. Milrinone and low vardiac output following cardiac surgery in infants: Is there a direct myocardial effect? Pediatr
Cardiol 2005; 26: 642-645.
131. Kliegman RM, Staton BF, St. Geme II JW, et al (ed). Nelson Textbook of Pediatrics 19th ed. Elsevier Saunders 2011: .294.
132. Keane JF, Lock JE, Fyler DC (ed). Nadas’Pediatric Cardiology 2nd edition. Elsevier Saunders 2006: .908.
133. Paradisis M, Evans N, Kluckow M, et al. Randomized trial of milrinone versus placebo for prevention of low systemic blood flow in very preterm
infants. J Pediatr 2009; 154: 189-195.
134. 山村英司. 心不全の薬物治療－フォスフォジエステラーゼ（PDE）Ⅲ阻害薬－. 日小循誌 2005; 21: 92-97.
135. Kantor PF, Abraham JR, Dipchand AI, et al. The impact of changing medical therapy on transplantation-free survival in pediatric dilated
cardiomyopathy. J Am Coll Cardiol 2010; 55: 1377-1384.
136. 村上智明. 小児心不全の治療. 日本医事新報 2009; 4454: 46-51.
137. 石川司朗, 青墳裕之, 越後茂之, 他. 小児心不全薬物療法ガイドライン. 日小循誌 2001; 17: 501-512.
138. Apukhtina TE, Doletskii AS, Avdeeva ON, et al. The use of sodium nitropursside in the treatment of heart failure in critically ill children. Anesteziol
Reanimatol 1991: 50-53.
139. 村上智明，八鍬聡，武田充人，他．大動脈二尖弁を基礎疾患とした大動脈弁閉鎖不全にアンジオテンシン変換酵素阻害薬が著効した一例．日児臨薬誌
2008; 19: 147-148.
140. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart
failure. N Engl J Med 1991; 325: 303-310.
141. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without
congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82:1724-1729.
142. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestve heart failure. Results of the Cooperative North Scandinavian
Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316: 1429-1435．
143. Mori Y, Nakazawa M, Tomimatsu H, et al. Long-term effect of angiotension-converting enzyme inhibitor in volume overloaded heart during growth:
a controlled pilot study. J Am Coll Cardiol 2000; 36: 270-275.
144. Hazama K, Nakazawa M, Momma K. Effective dose and cardiovascular effects of cilazapril in children with heart failure. Am J Cardiol 2001; 88:
801-805.
145. Bengur AR, Beekman RH, Rocchini AP, et al. Acute hemodynamic effects of captopril in children with congestive or restrictive cardiomyopathy.
Circulation 1991; 83: 523-527.
146. Lewis AB, Chabot M. The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated
cardiomyopathy. Pediatr Cardiol 1993; 14: 9-12.
147. 村上智明，武田充人，上野倫彦，他．心不全の急性増悪期にアンギオテンシン変換酵素阻害剤の種類により効果が異なった拡張型心筋症の一例. 医学と
薬学 2003; 49: 141-144.
148. Scammell AM, Arnold R, Wilkinson JL. Captopril in treatment of infant heart failure: a preliminary report. Int J Cardiol 1987; 16: 295-301.
149. Shaw NJ, Wilson N, Dickinson DF. Captopril in heart failure secondary to a left to right shunt. Arch Dis Child 1988; 63: 360-363.
150. Shaddy RE, Teitel DF, Brett C. Short-term hemodynamic effects of captopril infants with congestive heart failure. Am J Dis Child 1988; 142: 100-105.
151. Montigny M, Davignon A, Fouron JC, et al. Captopril in infants for congestive heart failure secondary to a large ventricular left-to right shunt. Am
J Cardiol 1989; 63: 631-633.
152. Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007; 298:
1171-1179.
153. Azeka E, Franchini Ramires JA, Valler C, et al. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment.
J Am Coll Cardiol 2002; 40: 2034-2038.
154. Bajcetic M, Kokic Nikolic A, Djukic M, et al. Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic
dilated cardiomyopathy: a 12-month, two-center, open-label study. Clin Therap 2008; 30: 702-714.
155. 村上智明，八鍬聡，上野倫彦，他．両方向性グレン手術･共通房室弁置換術後重症心不全に対しベータ遮断薬を導入し改善した心房錯位症候群の1例．心臓
2003; 35: 170-174．
156. Tuttle RR, Mills J. Dobutamine: Development of a new catecholamine to selectively increase cardiac contractility. Circ Res 1975; 36: 185-196.
157. Beregovich J, Bianchi C, D’Angelo R, et al. Haemodynamic effects of a new inotropic agent (dobutamine) in chronic cardiac failure. Br Heart J 1975;
37: 629-634.
158. Fowler MB, Alderman EL, Oesterls SN, et al. Dobutamine and dopamine after cardiac surgery: Greater augmentation of myocardial blood flow with
dobutamine. Circulation 1984; 70(3 Pt 2): I103-I111.
159. Lara Shekerdemian. Acute Circulatory Failure: Pharmacological and Mechanical Support. In Anderson RH, editor. Pediatric Cardiology, 3rd ed, UK,
Churchill Livingstone 2010: 239-255.
160. Athena FZ, Jeferey SB. Chapter 20 Pharmacology. In: David GN, editor: Rogers’ Textbook of Pediatric Intensive Care, 4th ed. Philadelphia, Lippincott
Williams & Wilkins 2008: 266-282.
161. DRUGDEX, Prod Info Dobutamine injection, 2005.
162. 中澤誠，他．心不全の治療，高尾篤良，他編，臨床発達心臓病学改訂3版．東京，中外医学社 2005: 249-262.
163. Mary EH, Ira MC. Ch62 Pediatric Emergencies and Resuscitation. In: Robert M. Kliegman MD, ed. Nelson Textbook of Pediatrics, 19th ed.
Philadelphia, Saunders 2011:279-296.
164. Shannon F. Manzi, Pharmd. Appendix B Emergency Drug Compendium. In: Gray R F, Stephan L, editor. Textbook of Pediatric Emergency
Medichine, 6th ed. Philadelphia, Lippincott Williams & Wilkins 2010: 1846-1880.
165. Edward J Baker. Formulary. In: Anderson RH, editor. Pediatric Cardiology, 3rd ed. UK, Churchill Livingstone 2010: 1299-1303.
166. Appendix. Principal Drug Used in Pediatric Cardiology. In: John FK, editor. NADAS’ Pediatric Cardiology, 2nd ed. Philadelphia, Saunders 2006:
907-909.
167. DRUGDEXⓇ 2.0. http://www.thomsonhc.com/home/dispatch
168. Schwartz PH, Eldadah MK, Newth CJ, et al. The pharmacokinetics of dobutamine in pediatric intensive care unit patients. Drug Metab Dispos 199;
19: 614-619.
169. Carlsson A, Waldeck B. A fluorimetric method for the determination of dopamine (3-hydroxytyramine). Acta Physiol Scand 1958; 44: 293-298.
170. Fowler NO, Shabetai R, Holmes JC. Adrenal medullary secretion during hypoxia, bleeding, and rapid intravenous infusion. Circ Res 1961; 9: 427-435.
171. Goldberg LI, Sjoerdsma A. Effects of several monoamine oxidase inhibitors on the cardiovascular actions of naturally occurring amines in the dog.
J Pharmacol Exp Ther 1959; 127: 212-218.
172. Holmes JC, Fowler NO. Direct cardiac effects of dopamine. Circ Res 1962; 10: 68-72.
173. Thompson BT, Cockrill BA. Renal-dose dopamine: A siren song? Lancet 1994; 344: 7-8.
174. Bhatt-Mehta V, Nahata MC, McClead RE, et al. Dopamine pharmacokinetics in critically ill newborn infants. Eur J Clin Pharmacol 1991; 40: 593-597.
175. Eldadah MK, Schwartz PH, Harrison R, et al. Pharmacokinetics of dopamine in infants and children. Crit Care Med 1991; 19: 1008-1011.
176. Golbranson FL, Lurie L, Vance RM, et al. Multiple extremity amputations in hypotensive patients treated with dopamine. JAMA 1980; 243: 1145-1146.
177. Resuscitation guidline 2010. Resuscitation Council (UK) Paediatric Advanced Life Support: 106-117.
178. Kleinman ME, de Caen AR, Chameides L, et al. Part 10: Pediatric Basic and Advanced Life Support 2010 International Consensus on
Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation 2010; 122: S466-S515.
179. α-and β -Adrenergic agonists, in AHFS Drug information 2010, Bethesda, American Society of Health-System Pharmacists: 1362-1373.
180. Fisher DG, et al. Pharmacokinetics of exogenous epinephrine in critically ill children. Crit Care Med 1993; 21: 111-117.
181. Silverberg AB, et al. Norepinephrine: hormone and neurotransmitter in man. Am J Physiol 1978; 234: E252-256.
182. Fonton M, Burch M. Understanding chronic heart failure. Arch Dis Child 2007; 92: 812-816.
183. Kay LD, Colan SD, Graham TP. Congestive heart failure in pediatric patients. Am Heart J 2001; 141: 923-928.
184. Systemic Hypertension. In Kliegman RM, Stanton BF, St Geme JW, et al. (eds): Nelson Textbook of Pediatrics, 19th rd. Elsevier Saunders,
Philadelphia, PA 2011: 1639-1647.
185. Connolly D, Rutkowski M, Auslender M, et al. The New York University Pediatric Heart FailureIndex: A new method of quantifying chronic heart failure
severity in children. J Pediatr 2001; 138: 644-648.
186. Blume ED, Freed MD, Colan SD. Congestive Heart Failure. In Keane JF, Lock JE, Fyler DC (eds): Nadas’s Pediatric Cardiology, 2nd ed. Elsevier
Saunders, Philadelphia, PA 2006: 83-95.
187. Graham TP, Jr., Bernard YD, Mellen BG, et al. Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional
study. J Am Coll Cardiol 2000; 36: 255-261.
188. Van der Vorst MMJ, Kist JE, van der Heijden AJ, st al. Diuretics in pediatrics. Ped Drugs 2006; 8: 245-264.
189. Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;
91: 457-465.
190. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103: 72-77.
191. Tsutamoto T, Wada A, Maeda K, et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure.
J Am Coll Cardiol 2000; 36: 838-844.
192. Qin W, Rudolph AE, Bond BR, et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 2003; 93: 69-76.
193. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized
Aldactone Evaluation Study Investigators. N Eng J Med 1999; 341: 709-717.
194. Hobbins SM, Fowler RS, Row RD, et al. Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease. Arch
Dis Child 1981; 56: 934-938.
195. Ambrosy A, Goldsmith S, Gheorghiade M. Tolvaptan for the treatment of heart failure: a reviw of the literature. Expert Opin Pharmacother 2011;
12: 961-976.
196. Schrier RW, Gross P, Gheorghiade M, el al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;
355: 2099-2112.
197. Yamamura Y, Sato O, Fujiki H. Vasopressin V2-receptor antagonist, tolvaptan, for treatment of heart failure. Nihon Rinsho 2007; 65 Suppl 5: 164-168.
198. 第20回川崎病全国調査成績. http://www.jichi.ac.jp/dph/kawasakibyou/20090902/kawasaki20reportv.pdf
199. 川崎病（ＭＣＬＳ，小児急性熱性皮膚粘膜リンパ節症候群）診断の手引き（厚生労働省川崎病研究班作成改訂5版）．
http://www.jskd.jp/info/pdf/tebiki.pdf
200. Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004; 364: 533-544.
A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995
Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001; 38: 2101-2113.
102. Reithmann C, Reber D, Kozlik-Feldmann R, et al. A postreceptor defect of adenylyl cyclase in severely failing myocardium from children with
congenital heart disease. Eur J Pharmacol 1997; 330: 79-86.
103. Läer S, Mir TS, Behn F, et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic
parameters. Am Heart J 2002; 143: 916-922.
104. Ohuchi H, Takasugi H, Ohashi H, et al. Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activities
in patients with congenital heart disease. Circulation 2003; 108: 2368-2676.
105. Rosenthal D, Chrisant MR, Edens E, et al. International Society for Heart and Lung Transplantation: Practice guidelines for management of heart
failure in children. J Heart Lung Transplant 2004; 12: 1313-1333.
106. Felker GM, O’Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 2001; 142: 393-401.
107. Lowes BD, Simon MA, Tsvetkova TO, et al. Inotropes in the beta-blocker era. Clin Cardiol 2000; 23: III11-6.
108. Silka M, Szmuszkovicz J. Arrhythmias and sudden cardiac death in pediatric heart failure. In: Shaddy R., Wernovsky G., ed. Pediatric Heart
Failure, Boca Raton, FL: Taylor & Francis 2005: 433-479.
109. Wagoner L.E., Starling RC, O’Connor CM. Cardiac function and heart failure. J Am Coll Cardiol 2006; 47: D18-D22.
110. Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006; 296: 1867-1876.
111. Azevedo VM, Santos MA, Albanesi Filho FM, et al. Outcome factors of idiopathic dilated cardiomyopathy in children: A long-term follow-up review.
Cardiol Young 2007; 17: 175-184.
112. Asanoi H, Kameyama T, Ishizaka S, et al. Energetically optimal left ventricular pressure for the failing human heart. Circulation 1996; 93: 67-73.
113. Kantor PF, Mertens LL. Clinical practice. Heart failure in children. Part I: clinical evaluation, diagnostic testing, and initial medical management.
Eur J Pediatr 2010; 169: 269-279.
114. Kantor PF, Mertens LL. Clinical practice. Heart failure in children. Part II: current maintenance therapy and new therapeutic approaches. Eur
J Pediatr 2010; 169: 403-410.
115. Osadchii OE. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. Cardiovasc Drugs Ther 2007;
21: 171-194.
116. Yan C, Miller CL, Abe J. Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res 2007; 100: 489-501.
117. Movsesian M, Stehlik J, Vandeput F, et al. Phosphodiesterase inhibition in heart failure. Heart Fail Rev 2009; 14: 255-263.
118. 梶本克也，指田由紀子，笠貫 宏．急性心不全に強心剤を使うべき．呼と循 2004; 52: 897-902.
119. Brixius K, Hoyer HK, Schwinger RHG. Ca2+-Sensitisers -A promising option to treat heart failure? Cardiovas Drug Therap 2005; 19: 423-428.
120. De Luca L, Colucci WS, Nieminen MS, et al. Evidencebased use of levosimendan in different clinical settings. Euro Heart J 2006; 27: 1908-1920.
121. Packer M. The Randomized multicenter Evaluation of Intravenous levosimendan Efficacy-2 (REVIVE-2) trial. Latebreaking Clinical Trials. American
Heart Association, Annual Scientific Session, Dallas, TX, 13-16 November 2005.
122. Mebazaa A. The SURVival of Patients with Acute Heart Failure in Need of IntraVEnous Inotropic Support (SURVIVE) trial. Late-breaking Clinical
Trials. American Heart Association, Annual Scientific Session. Dallas, TX, 13-16 November 2005.
123. 2009 Focused Updat: ACCF/AHAs Guidelines for the diagnosis and management of heart failure in adults. Circulation 2009; 119: 1977-2016.
124. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008; 29: 2388-2442.
125. Amsallem E, Kasparian C, Haddour G, et al. Phosphodiesterase III inhibitors for heart failure (Review). The Cochrane Library 2009, Issue 1.
CD002230.
126. Guideline Summary NGC-5205 Cincinnati Children’s Hospital Medical Center. Evidence-based care guideline for inotropic support with
phosphodiesterase inhibitors after repair of tetralogy of Fallot. Cincinnati (OH): Cincinnati Children’s Hospital Medical Center; 2006 Mar.
127. Guideline Summary NGC-5211 Cincinnati Children’s Hospital Medical Center. Evidence-based care guideline for inotropic support with
phosphodiesterase inhibitors after arterial switch operation. Cincinnati (OH): Cincinnati Children’s Hospital Medical Center; 2006 Aug
128. 循環器病の診断と治療に関するガイドライン. 急性心不全治療ガイドライン（2006年改訂版）. http://www.j-circ. or.jp/guideline/pdf/JCS2006_maruyama_h.pdf
129. Parissis JT, Farmakis D, Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev 2007; 12: 149-156.
130. Duggal B, Pratap U, Slavik Z, et al. Milrinone and low vardiac output following cardiac surgery in infants: Is there a direct myocardial effect? Pediatr
Cardiol 2005; 26: 642-645.
131. Kliegman RM, Staton BF, St. Geme II JW, et al (ed). Nelson Textbook of Pediatrics 19th ed. Elsevier Saunders 2011: .294.
132. Keane JF, Lock JE, Fyler DC (ed). Nadas’Pediatric Cardiology 2nd edition. Elsevier Saunders 2006: .908.
133. Paradisis M, Evans N, Kluckow M, et al. Randomized trial of milrinone versus placebo for prevention of low systemic blood flow in very preterm
infants. J Pediatr 2009; 154: 189-195.
134. 山村英司. 心不全の薬物治療－フォスフォジエステラーゼ（PDE）Ⅲ阻害薬－. 日小循誌 2005; 21: 92-97.
135. Kantor PF, Abraham JR, Dipchand AI, et al. The impact of changing medical therapy on transplantation-free survival in pediatric dilated
cardiomyopathy. J Am Coll Cardiol 2010; 55: 1377-1384.
136. 村上智明. 小児心不全の治療. 日本医事新報 2009; 4454: 46-51.
137. 石川司朗, 青墳裕之, 越後茂之, 他. 小児心不全薬物療法ガイドライン. 日小循誌 2001; 17: 501-512.
138. Apukhtina TE, Doletskii AS, Avdeeva ON, et al. The use of sodium nitropursside in the treatment of heart failure in critically ill children. Anesteziol
Reanimatol 1991: 50-53.
139. 村上智明，八鍬聡，武田充人，他．大動脈二尖弁を基礎疾患とした大動脈弁閉鎖不全にアンジオテンシン変換酵素阻害薬が著効した一例．日児臨薬誌
2008; 19: 147-148.
140. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart
failure. N Engl J Med 1991; 325: 303-310.
141. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without
congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82:1724-1729.
142. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestve heart failure. Results of the Cooperative North Scandinavian
Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316: 1429-1435．
143. Mori Y, Nakazawa M, Tomimatsu H, et al. Long-term effect of angiotension-converting enzyme inhibitor in volume overloaded heart during growth:
a controlled pilot study. J Am Coll Cardiol 2000; 36: 270-275.
144. Hazama K, Nakazawa M, Momma K. Effective dose and cardiovascular effects of cilazapril in children with heart failure. Am J Cardiol 2001; 88:
801-805.
145. Bengur AR, Beekman RH, Rocchini AP, et al. Acute hemodynamic effects of captopril in children with congestive or restrictive cardiomyopathy.
Circulation 1991; 83: 523-527.
146. Lewis AB, Chabot M. The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated
cardiomyopathy. Pediatr Cardiol 1993; 14: 9-12.
147. 村上智明，武田充人，上野倫彦，他．心不全の急性増悪期にアンギオテンシン変換酵素阻害剤の種類により効果が異なった拡張型心筋症の一例. 医学と
薬学 2003; 49: 141-144.
148. Scammell AM, Arnold R, Wilkinson JL. Captopril in treatment of infant heart failure: a preliminary report. Int J Cardiol 1987; 16: 295-301.
149. Shaw NJ, Wilson N, Dickinson DF. Captopril in heart failure secondary to a left to right shunt. Arch Dis Child 1988; 63: 360-363.
150. Shaddy RE, Teitel DF, Brett C. Short-term hemodynamic effects of captopril infants with congestive heart failure. Am J Dis Child 1988; 142: 100-105.
151. Montigny M, Davignon A, Fouron JC, et al. Captopril in infants for congestive heart failure secondary to a large ventricular left-to right shunt. Am
J Cardiol 1989; 63: 631-633.
152. Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007; 298:
1171-1179.
153. Azeka E, Franchini Ramires JA, Valler C, et al. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment.
J Am Coll Cardiol 2002; 40: 2034-2038.
154. Bajcetic M, Kokic Nikolic A, Djukic M, et al. Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic
dilated cardiomyopathy: a 12-month, two-center, open-label study. Clin Therap 2008; 30: 702-714.
155. 村上智明，八鍬聡，上野倫彦，他．両方向性グレン手術･共通房室弁置換術後重症心不全に対しベータ遮断薬を導入し改善した心房錯位症候群の1例．心臓
2003; 35: 170-174．
156. Tuttle RR, Mills J. Dobutamine: Development of a new catecholamine to selectively increase cardiac contractility. Circ Res 1975; 36: 185-196.
157. Beregovich J, Bianchi C, D’Angelo R, et al. Haemodynamic effects of a new inotropic agent (dobutamine) in chronic cardiac failure. Br Heart J 1975;
37: 629-634.
158. Fowler MB, Alderman EL, Oesterls SN, et al. Dobutamine and dopamine after cardiac surgery: Greater augmentation of myocardial blood flow with
dobutamine. Circulation 1984; 70(3 Pt 2): I103-I111.
159. Lara Shekerdemian. Acute Circulatory Failure: Pharmacological and Mechanical Support. In Anderson RH, editor. Pediatric Cardiology, 3rd ed, UK,
Churchill Livingstone 2010: 239-255.
160. Athena FZ, Jeferey SB. Chapter 20 Pharmacology. In: David GN, editor: Rogers’ Textbook of Pediatric Intensive Care, 4th ed. Philadelphia, Lippincott
Williams & Wilkins 2008: 266-282.
161. DRUGDEX, Prod Info Dobutamine injection, 2005.
162. 中澤誠，他．心不全の治療，高尾篤良，他編，臨床発達心臓病学改訂3版．東京，中外医学社 2005: 249-262.
163. Mary EH, Ira MC. Ch62 Pediatric Emergencies and Resuscitation. In: Robert M. Kliegman MD, ed. Nelson Textbook of Pediatrics, 19th ed.
Philadelphia, Saunders 2011:279-296.
164. Shannon F. Manzi, Pharmd. Appendix B Emergency Drug Compendium. In: Gray R F, Stephan L, editor. Textbook of Pediatric Emergency
Medichine, 6th ed. Philadelphia, Lippincott Williams & Wilkins 2010: 1846-1880.
165. Edward J Baker. Formulary. In: Anderson RH, editor. Pediatric Cardiology, 3rd ed. UK, Churchill Livingstone 2010: 1299-1303.
166. Appendix. Principal Drug Used in Pediatric Cardiology. In: John FK, editor. NADAS’ Pediatric Cardiology, 2nd ed. Philadelphia, Saunders 2006:
907-909.
167. DRUGDEXⓇ 2.0. http://www.thomsonhc.com/home/dispatch
168. Schwartz PH, Eldadah MK, Newth CJ, et al. The pharmacokinetics of dobutamine in pediatric intensive care unit patients. Drug Metab Dispos 199;
19: 614-619.
169. Carlsson A, Waldeck B. A fluorimetric method for the determination of dopamine (3-hydroxytyramine). Acta Physiol Scand 1958; 44: 293-298.
170. Fowler NO, Shabetai R, Holmes JC. Adrenal medullary secretion during hypoxia, bleeding, and rapid intravenous infusion. Circ Res 1961; 9: 427-435.
171. Goldberg LI, Sjoerdsma A. Effects of several monoamine oxidase inhibitors on the cardiovascular actions of naturally occurring amines in the dog.
J Pharmacol Exp Ther 1959; 127: 212-218.
172. Holmes JC, Fowler NO. Direct cardiac effects of dopamine. Circ Res 1962; 10: 68-72.
173. Thompson BT, Cockrill BA. Renal-dose dopamine: A siren song? Lancet 1994; 344: 7-8.
174. Bhatt-Mehta V, Nahata MC, McClead RE, et al. Dopamine pharmacokinetics in critically ill newborn infants. Eur J Clin Pharmacol 1991; 40: 593-597.
175. Eldadah MK, Schwartz PH, Harrison R, et al. Pharmacokinetics of dopamine in infants and children. Crit Care Med 1991; 19: 1008-1011.
176. Golbranson FL, Lurie L, Vance RM, et al. Multiple extremity amputations in hypotensive patients treated with dopamine. JAMA 1980; 243: 1145-1146.
177. Resuscitation guidline 2010. Resuscitation Council (UK) Paediatric Advanced Life Support: 106-117.
178. Kleinman ME, de Caen AR, Chameides L, et al. Part 10: Pediatric Basic and Advanced Life Support 2010 International Consensus on
Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation 2010; 122: S466-S515.
179. α-and β -Adrenergic agonists, in AHFS Drug information 2010, Bethesda, American Society of Health-System Pharmacists: 1362-1373.
180. Fisher DG, et al. Pharmacokinetics of exogenous epinephrine in critically ill children. Crit Care Med 1993; 21: 111-117.
181. Silverberg AB, et al. Norepinephrine: hormone and neurotransmitter in man. Am J Physiol 1978; 234: E252-256.
182. Fonton M, Burch M. Understanding chronic heart failure. Arch Dis Child 2007; 92: 812-816.
183. Kay LD, Colan SD, Graham TP. Congestive heart failure in pediatric patients. Am Heart J 2001; 141: 923-928.
184. Systemic Hypertension. In Kliegman RM, Stanton BF, St Geme JW, et al. (eds): Nelson Textbook of Pediatrics, 19th rd. Elsevier Saunders,
Philadelphia, PA 2011: 1639-1647.
185. Connolly D, Rutkowski M, Auslender M, et al. The New York University Pediatric Heart FailureIndex: A new method of quantifying chronic heart failure
severity in children. J Pediatr 2001; 138: 644-648.
186. Blume ED, Freed MD, Colan SD. Congestive Heart Failure. In Keane JF, Lock JE, Fyler DC (eds): Nadas’s Pediatric Cardiology, 2nd ed. Elsevier
Saunders, Philadelphia, PA 2006: 83-95.
187. Graham TP, Jr., Bernard YD, Mellen BG, et al. Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional
study. J Am Coll Cardiol 2000; 36: 255-261.
188. Van der Vorst MMJ, Kist JE, van der Heijden AJ, st al. Diuretics in pediatrics. Ped Drugs 2006; 8: 245-264.
189. Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;
91: 457-465.
190. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103: 72-77.
191. Tsutamoto T, Wada A, Maeda K, et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure.
J Am Coll Cardiol 2000; 36: 838-844.
192. Qin W, Rudolph AE, Bond BR, et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 2003; 93: 69-76.
193. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized
Aldactone Evaluation Study Investigators. N Eng J Med 1999; 341: 709-717.
194. Hobbins SM, Fowler RS, Row RD, et al. Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease. Arch
Dis Child 1981; 56: 934-938.
195. Ambrosy A, Goldsmith S, Gheorghiade M. Tolvaptan for the treatment of heart failure: a reviw of the literature. Expert Opin Pharmacother 2011;
12: 961-976.
196. Schrier RW, Gross P, Gheorghiade M, el al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;
355: 2099-2112.
197. Yamamura Y, Sato O, Fujiki H. Vasopressin V2-receptor antagonist, tolvaptan, for treatment of heart failure. Nihon Rinsho 2007; 65 Suppl 5: 164-168.
198. 第20回川崎病全国調査成績. http://www.jichi.ac.jp/dph/kawasakibyou/20090902/kawasaki20reportv.pdf
199. 川崎病（ＭＣＬＳ，小児急性熱性皮膚粘膜リンパ節症候群）診断の手引き（厚生労働省川崎病研究班作成改訂5版）．
http://www.jskd.jp/info/pdf/tebiki.pdf
200. Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004; 364: 533-544.
文献
小児期心疾患における薬物療法ガイドライン
Guidelines for Drug Therapy in Pediatric Patients with Cardiovascular Diseases （ JCS2012）
Guidelines for Drug Therapy in Pediatric Patients with Cardiovascular Diseases （ JCS2012）